Roche scores first U.S. approval of immunotherapy for breast cancer
The FDA on Friday approved the first immunotherapy for any kind of breast cancer: Roche's Tecentriq (atezolizumab).
Roche’s cancer immunotherapy Tecentriq (atezolizumab), a PD-L1 inhibitor, scored its fifth Food and Drug Administration approval on Friday, for advanced triple-negative breast cancer, but the fifth was a first: Before this decision, no immunotherapies had been approved for any form of breast cancer.
The approval, as is
